Do you want to read an article? Please log in or register.
Identification of pathway-based prognostic gene signatures in patients with multiple myeloma
Multiple Myeloma (MM)
Related content
SPECIAL REPORT
Multiple Myeloma (MM)
Traitement du myélome multiple récidivant/réfractaire
Multiple Myeloma (MM)
Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms
Leukemia.
Hoang PH, Dobbins SE, Cornish AJ, Chubb D1, Law PJ, Kaiser M, Houlston RS
doi: 10.1038/s41375-018-0103-3.
Multiple Myeloma (MM)
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy
J Clin Oncol.
Bridoux F, Arnulf B, Karlin L, Blin N, Rabot N, Macro M, Audard V, Belhadj K, Pegourie B, Gobert P, Cornec Le Gall E, Joly B, Karras A, Jaccard A, Augeul-Meunier K, Manier S, Royer B, Caillot D, Tiab M, Delbes S, Suarez F, Vigneau C, Caillard S, Arakelyan-Laboure N, Roos-Weil D, Chevret S, Fermand JP, MYRE study group
doi: 10.1200/JCO.20.00298.
RECOMMENDED
Multiple Myeloma (MM)
Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 1
Recommended by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1182/blood.2019003382.
Gynecologic Cancer
Prognostic gene expression signature for high-grade serous ovarian cancer
Ann Oncol.
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, AOCS Group., Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva D, Ramón Y Cajal T, García-Donas J, Polo SH, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz A, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, A deFazio, Gayther SA, García MJ, Henderson M, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ
doi: 10.1016/j.annonc.2020.05.019.
Breast Cancer
Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
JAMA Oncol.
Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H
doi: 10.1001/
COMMENTED
Multiple Myeloma (MM)
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
★ 1
Recommended and commented by
Prof. Dr Christoph Renner, Faculty Member
doi: 10.1016/S2352-3026(20)30070-3.
Multiple Myeloma (MM)
Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines
Eur Radiol.
Stacul F, Bertolotto M, Thomsen HS, Pozzato G, Ugolini D, Bellin MF, Bongartz G, Clement O, Heinz-Peer G, van der Molen A, Reimer P, Webb JAW; ESUR Contrast Media Safety Committee
doi: 10.1007/s00330-017-5023-5.
LymphomaMultiple Myeloma (MM)
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma
Blood.
Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N
doi: 10.1182/blood-2018-04-